Table 8 Survival analysis. Mean survival of the patients within all types (n = 194) and ccRCC (n = 120); univariate and multivariate cancer-specific survival in the patients with ccRCC according to analyzed immunohistochemical markers and clinic-pathologic parameters
Prognostic factors | Cancer-specific survival (months) | |||||||
|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | |||||||
All types mean (95% CI) | p-value | ccRCC mean (95% CI) | p-value | Hazard ratio (95% CI) | p-value | Hazard ratio (95%CI) | p-value | |
PRMT1 | ||||||||
positive | 78 (73–84) | 0.009* | 74 (66–82) | 0.029* | 0.504 (0.269–0.947) Ref. | 0.033* | 0.622 (0.326–1.188) | 0.150 |
negative | 56 (48–63) | 51 (42–61) | ||||||
ZEB1 | ||||||||
positive | 83 (76–91) | 0.011* | 80 (70–90) | 0.009* | 0.344 (0.140–0.801) | 0.014* | 0.367 (0.152–0.889) | 0.026 |
negative | 68 (61–74) | 52 (45–60) | ||||||
RUNX1 | ||||||||
positive | 75 (68–82) | 0.937 | 67 (60–74) | 0.506 | 0.872 (0.463–1.644) | 0.673 | N/A | |
negative | 69 (61–78) | 57 (48–66) | ||||||
TWIST1 | ||||||||
positive | 73 (68–78) | 0.886 | 67 (60–74) | 0.878 | 1.168 (0.159–8.553) | 0.879 | N/A | |
negative | 54 (34–75) | 54 (34–75) | ||||||
Grade | N/A | |||||||
Low | 67 (62–72) | <0.001* | 5.802 (3.000–11.222) | <0.001* | 6.284 (3.175–12.438) | <0.001* | ||
High | 25 (18–32) | |||||||
Stage | N/A | |||||||
Low | 70 (63–76) | <0.001* | 1.062 (0.849–1.330) | 0.597 | 1.187 (0.912–1.547) | 0.203 | ||
High | 48 (36–60) | |||||||
PN | 63 (51–74) | |||||||
Gender | ||||||||
Male | 75 (66–83) | 0.686 | 58 (51–65) | 0.736 | 1.123 (0.569–2.218) | 0.737 | N/A | |
Female | 72 (66–78) | 70 (58–81) | ||||||